INmune Bio Study Bolsters Stromal Cell Therapy Platform, Eyes 2026 BLA
Event summary
- INmune Bio published a peer-reviewed article in Cytotherapy highlighting the potential of mesenchymal stromal cell (MSC) therapies, specifically its CORDStrom™ platform.
- The article, co-authored by INmune Bio’s Dr. Nikita M. Patel, reviews current knowledge and identifies gaps in MSC therapy development.
- CORDStrom™ is currently being developed for recessive dystrophic epidermolysis bullosa (RDEB), with a Biologics License Application (BLA) and Marketing Authorization Application (MAA) expected in 2026.
- The CORDStrom™ platform utilizes a depot-delivery method and aims to create off-the-shelf, allogeneic, pooled hucMSCs.
The big picture
The MSC therapy field is gaining traction as a potential treatment for a range of inflammatory and autoimmune conditions, but faces challenges in standardization and efficacy. INmune Bio’s CORDStrom™ platform aims to address these challenges with its off-the-shelf, allogeneic approach. This publication underscores the company’s commitment to scientific rigor and positions CORDStrom™ as a potentially significant player in the evolving cell therapy landscape, though regulatory and clinical trial success remain critical.
What we're watching
- Regulatory Approval
- The success of the planned BLA and MAA filings in 2026 for RDEB will be a key indicator of CORDStrom™’s commercial viability and the platform’s broader potential.
- Platform Expansion
- How effectively INmune Bio can leverage the CORDStrom™ platform to develop indication-specific products beyond RDEB will determine its long-term revenue diversification.
- Scientific Validation
- The pace at which subsequent research builds upon the insights from this Cytotherapy publication will influence investor confidence and potential partnerships.
Related topics